77 related articles for article (PubMed ID: 27017703)
1. [EXPERIMENTAL PHARMACOKINETICS AND PHARMACODYNAMICS OF GB-115 DIPEPTIDE ANXIOLYTIC SUBSTANCES].
Kolik LG; Zherdev VP; Boiko SS; Konstantinopol'skii MA; Raskin SY; Gudasheva TA; Mart'yanov VA; Seredenin SB
Eksp Klin Farmakol; 2015; 78(11):30-4. PubMed ID: 27017703
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of three peroral dosage forms of new dipeptide anxiolytic drug GB-115].
Ivannikova EV; Boĭko SS; Zherdev VP; Raskin SIu; Blynskaia EV; Turchinskaia KG; Illarionov AA
Eksp Klin Farmakol; 2014; 77(7):31-4. PubMed ID: 25322652
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic activity of dipeptide GB-115 after oral administration.
Kolik LG; Konstantinopolsky MA; Ryibina IV; Povarnina PY; Gudasheva TA; Seredenin SB
Bull Exp Biol Med; 2013 Jun; 155(2):200-3. PubMed ID: 24130989
[TBL] [Abstract][Full Text] [Related]
4. [Effect of GB-115 dipeptide on anxiety in rats with model benzodiazepine withdrawal syndrome].
Kolik LG; Kadnikov IA; Zhukov VN; Gudasheva TA; Seredenin SB
Eksp Klin Farmakol; 2011; 74(10):7-11. PubMed ID: 22238979
[TBL] [Abstract][Full Text] [Related]
5. Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
Kolik LG; Gudasheva TA; Seredenin SB
Bull Exp Biol Med; 2012 Oct; 153(6):851-4. PubMed ID: 23113301
[TBL] [Abstract][Full Text] [Related]
6. [The absence of tolerance and withdrawal syndrome after the treatment with the new L-tryptophane-containing dipeptide anxiolytic GB-115].
Kolik LG; Garibova TL; Litvinova SA; Kuznetsova AL; Kapitsa IG; Kadnikov IA; Konstantinopol'skiĭ MA; Gudasheva TA; Voronina TA; Seredenin SB
Vestn Ross Akad Med Nauk; 2011; (7):37-42. PubMed ID: 21899090
[TBL] [Abstract][Full Text] [Related]
7. [Design and synthesis of cholecystokinin-4 dipeptide analogues with anxiolytic and anxiogenic activities].
Gudasheva TA; Kir'ianova EP; Kolik LG; Konstantinopol'skiĭ MA; Seredenin SB
Bioorg Khim; 2007; 33(4):413-20. PubMed ID: 17886432
[TBL] [Abstract][Full Text] [Related]
8. [Manifestations of the antinociceptive and anxiolytic properties of the compound GB-115: interactions of cholecystokinin and opioid systems].
Kolik LG; Zhukov VN; Seredenin SB
Eksp Klin Farmakol; 2007; 70(2):8-11. PubMed ID: 17523442
[TBL] [Abstract][Full Text] [Related]
9. Dependence of anxiolytic effects of the dipeptide TSPO ligand GD-23 on neurosteroid biosynthesis.
Gudasheva TA; Deeva OA; Yarkova MA; Seredenin SB
Dokl Biochem Biophys; 2016 Jul; 469(1):298-301. PubMed ID: 27599516
[TBL] [Abstract][Full Text] [Related]
10. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
[TBL] [Abstract][Full Text] [Related]
11. Dipeptide Tyr-Leu (YL) exhibits anxiolytic-like activity after oral administration via activating serotonin 5-HT1A, dopamine D1 and GABAA receptors in mice.
Kanegawa N; Suzuki C; Ohinata K
FEBS Lett; 2010 Feb; 584(3):599-604. PubMed ID: 20005875
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Anxiolytic Activity Evaluation of N-Acyltryptophanyl- Containing Dipeptides, Potential TSPO Ligands.
Gudasheva TA; Deeva OA; Mokrov GV; Dyabina AS; Yarkova MA; Seredenin SB
Med Chem; 2019; 15(4):383-399. PubMed ID: 30457052
[TBL] [Abstract][Full Text] [Related]
13. The New Dipeptide TSPO Ligands: Design, Synthesis and Structure-Anxiolytic Activity Relationship.
Gudasheva TA; Deeva OA; Pantileev AS; Mokrov GV; Rybina IV; Yarkova MA; Seredenin SB
Molecules; 2020 Nov; 25(21):. PubMed ID: 33158242
[TBL] [Abstract][Full Text] [Related]
14. The first dipeptide ligand of translocator protein: Design and anxiolytic activity.
Gudasheva TA; Deeva OA; Mokrov GV; Yarkov SA; Yarkova MA; Seredenin SB
Dokl Biochem Biophys; 2015; 464():290-3. PubMed ID: 26518550
[TBL] [Abstract][Full Text] [Related]
15. Aromatic amino acid-leucine dipeptides exhibit anxiolytic-like activity in young mice.
Mizushige T; Kanegawa N; Yamada A; Ota A; Kanamoto R; Ohinata K
Neurosci Lett; 2013 May; 543():126-9. PubMed ID: 23570730
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test.
Gudasheva TA; Konstantinopol'skii MA; Ostrovskaya RU; Seredenin SB
Bull Exp Biol Med; 2001 May; 131(5):464-6. PubMed ID: 11550054
[TBL] [Abstract][Full Text] [Related]
17. Anxiolytic effect of clonazepam in female rats: grooming microstructure and elevated plus maze tests.
Nin MS; Couto-Pereira NS; Souza MF; Azeredo LA; Ferri MK; Dalprá WL; Gomez R; Barros HM
Eur J Pharmacol; 2012 Jun; 684(1-3):95-101. PubMed ID: 22487059
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests.
Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A
Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144
[TBL] [Abstract][Full Text] [Related]
19. The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze.
Eroğlu L; Güven O
Pharmacol Res; 1998 Feb; 37(2):137-43. PubMed ID: 9572069
[TBL] [Abstract][Full Text] [Related]
20. [Effects of N-stearoylethanolamine on the emotionality and learning ability of rats].
Bondarenko OV; Hula NM; Makarchuk MIu; Horid'ko TM; Kovalenko OA
Fiziol Zh (1994); 2014; 60(5):52-61. PubMed ID: 25566671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
